The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.

A peptide comprises an amino acid sequence of SEQUENCE ID NO. 1, in which the sequence has 1, 2 or 3 amino acid changes. The peptide has utility in treatment of cardiovascular disease and neurodegenerative disease.

The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.

The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.

A method for treating irritable bowel disease or irritable bowel syndrome is provided. The method may include steps of providing a patient suffering from irritable bowel disease or irritable bowel syndrome; providing a dosage of an Angiotensin II modulator and a dosage of an GABA-a agonist; and co-administering the dosages. The method may further include a step of increasing prostacyclin release in blood vessels of the patient's mesenteric or splanchnic circuit through action of the Angiotensin II modulator and the GABA-a agonist. The Angiotensin II modulator may include at least one of an ARB and an ACE Inhibitor, wherein the ARB is an Angiotensin II, type 1 receptor antagonist. A dosage of an AT2 agonist may also be provided and co-administered.

A method for treating irritable bowel disease or irritable bowel syndrome is provided. The method may include steps of providing a patient suffering from irritable bowel disease or irritable bowel syndrome; providing a dosage of an Angiotensin II modulator and a dosage of an GABA-a agonist; and co-administering the dosages. The method may further include a step of increasing prostacyclin release in blood vessels of the patient's mesenteric or splanchnic circuit through action of the Angiotensin II modulator and the GABA-a agonist. The Angiotensin II modulator may include at least one of an ARB and an ACE Inhibitor, wherein the ARB is an Angiotensin II, type 1 receptor antagonist. A dosage of an AT2 agonist may also be provided and co-administered.

The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and pain.

Described herein are pharmaceutical compositions comprising terlipressin and therapeutic methods for using them.

Disclosed herein are compositions including cyclodextrin and Nle3-A(1-7) [Asp-Arg-Me-Tyr-Ile-His-Pro (SEQ ID NO: 1)] and their use in treating various disorders.

The present invention provides, among other things, methods of treating a cardiac disease or condition in a patient having muscular dystrophy that can include administering to a subject suffering from, susceptible, or diagnosed with muscular dystrophy an angiotensin (1-7) peptide.